84.49 USD
+3.82 (+4.74%)
At close: Feb 6, 2026
84.49 USD
0 (0%)
Pre-Market: 2/9/2026, 4:25:05 AM
Taking everything into account, PTGX scores 5 out of 10 in our fundamental rating. PTGX was compared to 523 industry peers in the Biotechnology industry. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability. PTGX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- PTGX had positive earnings in the past year.
- In the past year PTGX had a positive cash flow from operations.
- PTGX had negative earnings in 4 of the past 5 years.
- In the past 5 years PTGX reported 4 times negative operating cash flow.
1.2 Ratios
- The Return On Assets of PTGX (6.54%) is better than 92.54% of its industry peers.
- With an excellent Return On Equity value of 7.11%, PTGX belongs to the best of the industry, outperforming 91.20% of the companies in the same industry.
- PTGX has a Return On Invested Capital of 2.29%. This is amongst the best in the industry. PTGX outperforms 89.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROIC | 2.29% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PTGX has a better Profit Margin (21.94%) than 94.26% of its industry peers.
- Looking at the Operating Margin, with a value of 9.09%, PTGX belongs to the top of the industry, outperforming 91.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PTGX is destroying value.
- PTGX has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, PTGX has more shares outstanding
- PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 56.81 indicates that PTGX is not in any danger for bankruptcy at the moment.
- PTGX's Altman-Z score of 56.81 is amongst the best of the industry. PTGX outperforms 96.75% of its industry peers.
- PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 56.81 |
ROIC/WACC0.18
WACC12.44%
2.3 Liquidity
- A Current Ratio of 13.05 indicates that PTGX has no problem at all paying its short term obligations.
- With an excellent Current ratio value of 13.05, PTGX belongs to the best of the industry, outperforming 88.53% of the companies in the same industry.
- PTGX has a Quick Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 13.05, PTGX belongs to the best of the industry, outperforming 88.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 |
3. Growth
3.1 Past
- PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.69%.
- Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -35.39% in the last year.
- PTGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 352.10% yearly.
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
3.2 Future
- Based on estimates for the next years, PTGX will show a very negative growth in Earnings Per Share. The EPS will decrease by -10.73% on average per year.
- The Revenue is expected to grow by 8.27% on average over the next years. This is quite good.
EPS Next Y-146.69%
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%
EPS Next 5Y-10.73%
Revenue Next Year-84.15%
Revenue Next 2Y-5.62%
Revenue Next 3Y-24.47%
Revenue Next 5Y8.27%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 136.27, the valuation of PTGX can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 89.10% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.93, PTGX is valued quite expensively.
- PTGX is valuated quite expensively with a Price/Forward Earnings ratio of 226.46.
- Based on the Price/Forward Earnings ratio, PTGX is valued cheaply inside the industry as 87.76% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 27.77. PTGX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.27 | ||
| Fwd PE | 226.46 |
4.2 Price Multiples
- PTGX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTGX is cheaper than 89.29% of the companies in the same industry.
- 91.78% of the companies in the same industry are more expensive than PTGX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 82.91 | ||
| EV/EBITDA | 207.54 |
4.3 Compensation for Growth
- A cheap valuation may be justified as PTGX's earnings are expected to decrease with -32.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%
5. Dividend
5.1 Amount
- PTGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
84.49
+3.82 (+4.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-19 2026-02-19/amc
Inst Owners114.02%
Inst Owner Change2.91%
Ins Owners1.01%
Ins Owner Change2.09%
Market Cap5.28B
Revenue(TTM)209.22M
Net Income(TTM)45.91M
Analysts84.21
Price Target102.55 (21.38%)
Short Float %13.65%
Short Ratio9.11
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.88%
Max EPS beat(2)6.78%
EPS beat(4)4
Avg EPS beat(4)133.89%
Min EPS beat(4)4.88%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)266.75%
EPS beat(12)10
Avg EPS beat(12)179.39%
EPS beat(16)14
Avg EPS beat(16)139.25%
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)27.04%
Revenue beat(4)2
Avg Revenue beat(4)57.59%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)5
Avg Revenue beat(8)57.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.69%
PT rev (3m)30.33%
EPS NQ rev (1m)12.44%
EPS NQ rev (3m)19.83%
EPS NY rev (1m)-0.34%
EPS NY rev (3m)3.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-67.03%
Revenue NY rev (1m)-23.46%
Revenue NY rev (3m)-18.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.27 | ||
| Fwd PE | 226.46 | ||
| P/S | 25.25 | ||
| P/FCF | 82.91 | ||
| P/OCF | 80.69 | ||
| P/B | 8.18 | ||
| P/tB | 8.18 | ||
| EV/EBITDA | 207.54 |
EPS(TTM)0.62
EY0.73%
EPS(NY)0.37
Fwd EY0.44%
FCF(TTM)1.02
FCFY1.21%
OCF(TTM)1.05
OCFY1.24%
SpS3.35
BVpS10.32
TBVpS10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROCE | 2.89% | ||
| ROIC | 2.29% | ||
| ROICexc | 18.62% | ||
| ROICexgc | 18.62% | ||
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A | ||
| FCFM | 30.45% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 121.94% | ||
| Cap/Sales | 0.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 320.17% | ||
| Profit Quality | 138.78% | ||
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 | ||
| Altman-Z | 56.81 |
F-Score5
WACC12.44%
ROIC/WACC0.18
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
EPS Next Y-146.69%
EPS Next 2Y-70.2%
EPS Next 3Y-32.32%
EPS Next 5Y-10.73%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
Revenue Next Year-84.15%
Revenue Next 2Y-5.62%
Revenue Next 3Y-24.47%
Revenue Next 5Y8.27%
EBIT growth 1Y-87.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-196.54%
EBIT Next 3Y-33.52%
EBIT Next 5YN/A
FCF growth 1Y153.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y155.09%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
What is the valuation status for PTGX stock?
ChartMill assigns a valuation rating of 4 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Fairly Valued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.
What is the valuation of PROTAGONIST THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 136.27 and the Price/Book (PB) ratio is 8.18.
What is the expected EPS growth for PROTAGONIST THERAPEUTICS INC (PTGX) stock?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -146.69% in the next year.